Related Experiment Videos
Heart failure: SGLT2 inhibitors and heart failure -- clinical implications
1Diabetes Unit, Department of Internal Medicine, Hadassah Hebrew University Hospital, Kiryat Hadassah, PO Box 12000, Jerusalem 91120, Israel.
Abstract:
The latest findings from the EMPA-REG OUTCOME trial show a 34% reduction in hospitalization for heart failure or cardiovascular death in patients receiving empagliflozin, a sodium/glucose cotransporter 2 (SGLT2) inhibitor, compared with placebo. These outstanding results call for discussion of the clinical implications, and in-depth studies of the mechanisms of action of SGLT2 inhibitors.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Diuretics
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VI: Adjunct Therapies